Group items tagged

An old proverb that comes to mind in the pursuit of the twin objectives of serenity and health is this: the mind and the body are inexorably intertwined. This essential, often overlooked, connection is at the heart of our ability to manage stress and foster a sense of well-being. But how does one truly achieve relaxation, and how does it translate to a healthier way of living? From ancient practices to modern breakthroughs, the path to stress relief and overall health is illuminated by a multifaceted approach that combines mindfulness, diet, exercise, and even the judicious use of calming products. The nexus between stress relief and well-being is rich and layered. By exploring various strategies, we can uncover the tapestry of tranquility that ultimately leads to a richer, more vital life. Relaxation Leads to a Healthier Mind and Body Relaxation is not just a warm bath or an hour of Netflix; it is the conscious unclenching of the mind and the body's release of tension. It's a critical ingredient in the complex recipe for overall health and plays a significant role in the functioning of the immune system, the maintenance of a healthy heart, and the regulation of moods. To relax, people take wellness CBD gummies that offer a natural, convenient route to unwind without the psychedelic effects often associated with the substance. Relaxation techniques also encompass meditation, deep breathing, progressive muscle relaxation, and guided imagery. Each method has its loyal practitioners, but the central tenet remains the same - in relaxation lies a wellspring of health.

ITV on Tuesday (Aug 15) said it had agreed to invest in pain relief brand Flarin Holdings Ltd, making it the British broadcaster's first consumer healthcare investment. The company has agreed to subscribe for £2 million worth of shares in Flarin, with an option to subscribe for two more tranches of 1.5 million pounds each. In return, Flarin would get advertising space across ITV's channels and ITVX. ITV said its investment will "help Flarin build mass market brand awareness by bringing the brand to millions of consumers via ITV platforms. This will be a step change in the size of the campaign and the approach to scaling the Flarin brand to date." Director of ITV AdVentures, Sheena Amin, said: "It's fantastic to be announcing our latest Media for Equity investment into Flarin. With its innovative and patented lipid technology, Flarin offers many unique benefits to those suffering from joint and muscular pain compared to any other product on the market. Flarin is already one of the fastest growing analgesics in the market and I am confident that we will see the company grow to new heights following a brand building campaign across ITV."

GSK is helping pharmacists to tap into Self Care Week this November, and remind patients how they can adopt a more proactive approach in looking after their health. This includes treating ailments, such as joint pain, over the counter to take pressure off GPs where possible. Joint pain complaints take up a significant amount of general practice resource with 57 per cent of pain presentations reported relating to joint pain[1], as well as 23 per cent of sufferers feeling as though their pain impacts their quality of life[2]. Many of these complaints and ailments could be addressed with treatment recommendations from a pharmacist with support from Voltarol. GSK, manufacturer of Voltarol (the market leader in the pain relief topic category[3]), offers support through both its products and resources in hopes to advocate over-the-counter treatments.

Panadol launched a new purpose-led brand idea as part of a multi-channel campaign across Great Britain and Ireland. With nine out of 10 people suffering "everyday pain" and 65% of people saying they can't be happy when they are in pain[1], globally, the campaign reiterates the brand's commitment to holistic pain management by focusing on the acute pain recovery journey. Rooted in deep consumer understanding, the campaign idea celebrates that never-talked-about moment of realisation when you start to feel the release from pain. The new brand idea will bring to life the emotional transformation that those suffering from acute pain undergo, emphasising the role that Panadol can play in alleviating their pain. The Panadol campaign follows a period of strong sales growth for the brand, outperforming the category's own expansion by more than double[2]. This has been driven by shoppers who are searching for fast and effective pain relief products, such as Panadol's hero variants, including Panadol Extra Advance Tablets (paracetamol, caffeine), which has seen its growth almost doubled[3], as well as Panadol Advance Tablets (paracetamol) and Panadol Extra Advance Tablets. Monica Michalopoulou, GBI Marketing Director, said: "After two years of pandemic restrictions, now more than ever, people want to get back to their normal lives and to the people they love. But with pain preventing many of us from connecting with those we love or from doing the things we enjoy the most, we want to help consumers by understanding their pain journey and reassuring them on the treatments we can provide. This "Release" moment is so important for pain sufferers, and we hope our new brand campaign can shine a light on the role that Panadol can play in pain relief".

Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals that use of systemic (oral and injectable) Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and diclofenac is contraindicated in the last trimester of pregnancy (after 28 weeks of pregnancy). It has advised that patients who are unsure whether pain relief medicine they are taking is an anti-inflammatory (NSAID), to speak to doctor, midwife, or pharmacist. Some non-prescription pain relief medicines may contain more than one active drug, therefore it is important to read the box or the leaflet provided with the medicine to see if it contains an NSAID like ibuprofen. The use of any non-prescription medicine for the management of pain during pregnancy should be for the shortest possible time at the lowest possible dose, suggested MHRA.

The Pharmaceutical Services Negotiating Committee announced last week that it is in discussions with the Department of Health and Social Care (DHSC) and NHS England about relieving capacity pressures, such as a relaxation of pharmacy opening hours requirements. PSNC is also scheduling webinars to talk with contactors about the steps they might be willing to take in future, to cut costs, should emergency financial relief fail to materialise. The pharmacy regulator reported that many of its members felt that it was no longer tenable for pharmacies to keep offering all of the free and non-core services to patients that they would like to, and that all contractors should consider what steps they could take to try to safeguard their businesses and their core services for patients. PSNC is also keen to talk to contractors about their current situation and the steps they might be willing to take in future, should emergency relief not be forthcoming.

Boots has expanded its partnership with Deliveroo to cover 125 stores in the UK, offering delivery of a wide range of health and beauty products up and down the country. The company announced last year that it had entered into an exclusive partnership with Deliveroo to provide 400 plus health and beauty products to consumers at their doorsteps. The pharmacy multiple has been delivering over-the-counter cough, cold and flu symptom relief products, paracetamol, vitamins and digital thermometers through Deliveroo. The partnership has been part of the business' continued investment in digital technology to provide customers with a more convenient and personal shopping experience. Popular and new products available on Deliveroo include cough, cold and flu symptom relief products, paracetamol, vitamins, digital thermometers, period and sexual wellbeing products including sanitary towels, condoms and pregnancy tests among other health and beauty products. Boots is now available via Deliveroo for the first time to customers in major cities including Manchester, Glasgow, Belfast, Bristol, Sheffield, Coventry, Plymouth, Exeter, Middlesbrough, York, Aberdeen and Inverness.

The Mentholatum Company is shaking up the dry eye market with a clinically proven, world-leading advanced dry eye relief formulation. Rohto Dry Aid relieves EIGHT symptoms of dry eye and helps hydrate, protect and restore the tear film. Elvy Mardjono, senior brand manager for Rohto Dry Aid, says: "Rohto Dry Aid, with its Tearshield Technology™ acts fast, is non-blurry and delivers soothing relief for up to 12 hours." Rohto Dry Aid's Tearshield Technology™ formulation is kind to the eyes and designed to mimic the properties of the natural tear film, providing the protection and hydration required to tackle dry spots and restore all layers of the natural tear film.

National pharmacy bodies have welcomed two VAT changes related to community pharmacy services announced in the Spring budget on Wednesday (15 March) but were disappointed that the budget brought no further relief for the sector in a crippling funding crisis. It was announced that from 1 May 2023, VAT exemption on healthcare would be extended to include medical services carried out by staff directly supervised by registered pharmacists. The government will also extend zero rate on prescriptions to medicines supplied through Patient Group Directions. This measure will be introduced in autumn 2023. HM Treasury said these measures were being introduced to ensure that the VAT system keeps up with changes to how the NHS operates and how healthcare is delivered across the country. More widely, Chancellor Jeremy Hunt promised to halve inflation and said that the NHS would soon publish its long-term workforce plan.

Community Pharmacy England (CPE) has expressed dissatisfaction with the spring budget as it brings "no specific relief" for the community pharmacy sector, which is grappling with "soaring costs and severe medicine supply and pricing issues." UK Chancellor Jeremy Hunt announced his Spring Budget on Wednesday, confirming an extra £2.5 billion in day-to-day revenue funding for the NHS in England in 2024-25 and a new NHS productivity plan worth £3.4bn to modernise IT systems. The Chancellor said that day-to-day spending would grow by 1 per cent per year on average in real terms, and the productivity plan is estimated to "unlock £35 billion worth of savings" from 2025-26 to 2029-30. However, CPE chief executive, Janet Morrison commented that the budget has "no obvious good news" for community pharmacies who need "urgent relief from the ongoing unsustainable funding and operational pressures" they are facing. Morrison described the investment in Pharmacy First as "the most significant investment in pharmacies in a decade", but emphasised the need for further support to stabilise the sector and its core contractual arrangements.

Holland & Barrett, the UK's leading wellness retailer, has become the latest retailer regulatory member of PAGB, the consumer healthcare association. PAGB represents the manufacturers of branded over-the-counter (OTC) medicines, self care medical devices and food supplements in the UK. Holland & Barrett's decision to PAGB follows its recent introduction of a selected range of OTC and healthcare products in its stores across the UK. These include painkillers, cough and cold medicines, children's health essentials, hay fever relief, as well as skin and gastrointestinal products. With this expansion, the retailer aims to not only help customers to stay well, but also provide relief when needed.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised healthcare professionals to ensure appropriate patient counselling takes place and patients are aware of the missing information on the patient information leaflet (PIL) of Decongestant Tablets and Decongestant with Pain Relief Tablets. The advise came after Boots has identified an error with the printed PIL provided with batches of the tablets. Check the website for more information.

Well Pharmacy, a subsidiary company of Bestway Group is donating US$400,000 worth of medicines to help the victims of those impacted by the recent flooding in Pakistan. The Bestway Group has raised funds to the tune of $2.3 million, which will be deployed urgently on the ground in Pakistan. The monies raised has been pledged to build homes (or shelters) for 5,000 families, provide usable water for more than 100,000 individuals and provide food and medical supplies to over 20,000 people. In addition to appealing for donations, the Group held a fund-raising event (23 September) at London's Intercontinental on Park Lane, which was attended by over 650 guests including the Lord Chancellor, the Deputy State Bank of Pakistan, UK Cabinet Ministers, and Members of Parliament in addition to leading City' figures and business community. The Lord Chancellor Rt Hon Brandon Lewis MP said that the British Government has committed funds of £16.5 million for Pakistan and we are dealing with wider climate change issues as well and we are committing to that effort.

Learn about the different migraine remedy that helps reduce its painful impact. These hacks are both the best migraine relief and reliable treatment.

The US Food and Drug Administration (FDA) has approved the Novartis drug, Cosentyx, (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. HS is a chronic, progressive and painful disease which affects one in 100 people worldwide, and has limited treatment options. "Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS," said the Swiss company. The FDA approval was based on robust Phase III data (SUNSHINE and SUNRISE studies) in which Cosentyx showed rapid relief from HS symptoms as early as Week 21.

Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.

The Pharmaceutical Services Negotiating Committee (PSNC) has rejected Department of Health and Social Care (DHSC) and NHS England's proposal on price concessions reform and relief measures to ease pressure on pharmacies. The Committee called the proposal 'insufficient' to meet the sector's needs considering the impact of the current crisis, reflecting on the economic pressures that accelerated through the autumn and winter. The Ministers and other decision-makers have shown their interest in the potential role of community pharmacy, particularly in using a Pharmacy First approach and making use of PGDs and the skills of independent prescribers. But the Committee had made clear to them that without new money this is all a pipedream. "We need an urgent injection of funds into the sector, otherwise we will continue to see a degradation of services and eventual collapse of the network. The Committee is clear that there is no further place for warm words while pharmacy collapses," said PSNC. The Committee reflected that the 5-year CPCF agreement had been based on working together to create the capacity and context necessary to deliver the shift towards greater service delivery. Not only has that capacity-release not happened due to slow progress by Government, but pharmacies have also been burdened with these additional, and insurmountable, challenges.

Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.

VioPatch Pain Relieving Transdermal Patches are the perfect example of staying away from pain. Works for around 12 hours continuously, it provides more satisfaction..